- Home
- SNGX vs APVO Comparison
SNGX vs APVO Comparison
Compare SNGX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- APVO
- Stock Information
- Founded
- SNGX 1987
- APVO 2016
- Country
- SNGX United States
- APVO United States
- Employees
- SNGX N/A
- APVO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- APVO Health Care
- Exchange
- SNGX Nasdaq
- APVO Nasdaq
- Market Cap
- SNGX 6.5M
- APVO 4.1M
- IPO Year
- SNGX 1987
- APVO N/A
- Fundamental
- Price
- SNGX $1.36
- APVO $3.03
- Analyst Decision
- SNGX Strong Buy
- APVO Strong Buy
- Analyst Count
- SNGX 1
- APVO 1
- Target Price
- SNGX $6.00
- APVO $5,920.00
- AVG Volume (30 Days)
- SNGX 2.7M
- APVO 474.6K
- Earning Date
- SNGX 08-08-2025
- APVO 08-07-2025
- Dividend Yield
- SNGX N/A
- APVO N/A
- EPS Growth
- SNGX N/A
- APVO N/A
- EPS
- SNGX N/A
- APVO N/A
- Revenue
- SNGX $2,342.00
- APVO N/A
- Revenue This Year
- SNGX N/A
- APVO N/A
- Revenue Next Year
- SNGX N/A
- APVO N/A
- P/E Ratio
- SNGX N/A
- APVO N/A
- Revenue Growth
- SNGX N/A
- APVO N/A
- 52 Week Low
- SNGX $1.09
- APVO $2.81
- 52 Week High
- SNGX $7.20
- APVO $405.52
- Technical
- Relative Strength Index (RSI)
- SNGX 44.21
- APVO 36.57
- Support Level
- SNGX $1.24
- APVO $2.86
- Resistance Level
- SNGX $1.40
- APVO $3.05
- Average True Range (ATR)
- SNGX 0.14
- APVO 0.16
- MACD
- SNGX 0.03
- APVO 0.21
- Stochastic Oscillator
- SNGX 34.18
- APVO 50.00
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.